RT Journal Article SR Electronic T1 Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P407 VO 40 IS Suppl 56 A1 Tamila Martynyuk A1 Kirill Zykov A1 Olga Antonova A1 Olga Arkhipova A1 Ekaterina Kobal A1 Valery Masenko A1 Sergey Nakonechnikov A1 Irina Chazova YR 2012 UL http://erj.ersjournals.com/content/40/Suppl_56/P407.abstract AB Aim: to assess the influence of endothelin receptor antagonist Bosentan on cellular Immunity parameters in pts with idiopathic pulmonary arterial hypertension (IPAH).Methods: In the single-center comparative study we included 35 pts aged 35,2±9,6ys with IPAH confirmed by RHC (WHO Functional Class (FC) II-IV) without systemic inflammation signs. On top of stable therapy for at least 3 months Bosentan therapy was started 62,5 mg twice daily for 4 wks. At wk4 the patients were randomized 1:1 by the envelope method to have bosentan 125 or 250 mg/day. At baseline, at wk3 and wk12 visits the pts underwent the clinical and lab assessment (FC, 6-minute walking test (6-MWT), Echo, RHC,routine lab+CD-markers assessed by (fluorometry (Beckman Coulter FC 500).Results: All cellular immunity parameters of IPAH pts remained within normal limits.View this table:Conclusion: 12wk therapy with Bosentan changed CD-markers levels. The daily dose of 125mg resulted in the increase of B-lymphocytes levels and slight decrease of activated T lymphocytes, In patients treated with Bosentan 250 mg we found decreased numbers of activated B - and T-lymphocytes.